Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease
Objective: To evaluate valbenazine’s effects on chorea across body regions in adults with Huntington’s disease (HD) using data from KINECT®-HD (NCT04102579). Background: Once-daily valbenazine is…Decreased Disease Burden in Motor-Related HD-HI Domains Among Adults With Huntington’s Disease Treated With Valbenazine
Objective: To evaluate the effects of valbenazine (VBZ) on mobility, abnormal movements, and hand/arm function as assessed using the Huntington’s Disease Health Index (HD-HI). Background:…Long-Term Safety and Efficacy of Valbenazine for Treating Huntington’s Disease Chorea
Objective: To present safety and efficacy results from a long-term study of once-daily valbenazine for chorea associated with Huntington’s disease (HD). Background: In a 12-week…Adult-Onset Post-Pump Chorea: A Rare Manifestation Post-Cardiac Surgery in a Puerto Rican Patient
Objective: To report the first case of adult-onset post-pump chorea in Puerto Rico and raise awareness of our patient’s atypical age and onset of clinical…Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders
Objective: We review the real-world prescribing practices and patient experiences with VMAT2 inhibitors in children. Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors are often prescribed…Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for TD: a Case Series
Objective: Describe clinical characteristics and changes in mental, socioemotional, and physical domains of individuals with tardive dyskinesia (TD) after valbenazine (VBZ) treatment. Background: Prior research…Striatal Dysfunction in Parkinson’s Disease Progression: A 18F-9-fluoropropyl-(+)-dihydrotetrabenazine(18F-AV133) PET Study
Objective: To investigate the patterns of striatal 18F-AV133 uptake in relation to disease progression across different stages of PD and to examine its relationship with…Evaluating the association between cognitive impairment and striatal VMAT2 binding using [18F]AV-133 PET in Parkinson’s disease
Objective: To evaluate the association between cognitive deficits and striatal vesicular monoamine transporter type 2 (VMAT2) binding in participants with Parkinson’s disease (PD) using [18F]AV-133…Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson’s Disease Severity and Progression
Objective: Compare VMAT2 PET signal with DATscan at baseline and over time, and evaluate their correlations with MDS-UPDRS III. Background: DATscan is a Parkinson’s disease…The effect of APOE ε4 on striatal vesicular monoamine transporter-2 density in Parkinson’s disease
Objective: To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).To evaluate the effect…
- 1
- 2
- 3
- …
- 6
- Next Page »